TickerTalks
Browse all tickers →
TickerTalks›$OSCR
OSOSCR

Oscar Health, Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 53% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (2.1K/wk), no spike
$OSCR·$7.9B·Medical - Healthcare Plans·Healthcare
$29.03+0.6%YTD+99.7%1Y+88.0%
Mentions · last 7 days
2026-07-10: 732 posts2026-07-11: 82 posts2026-07-12: 87 posts2026-07-13: 283 posts2026-07-14: 196 posts2026-07-15: 331 posts2026-07-16: 366 posts2,122+14%
Price updated 11m ago·X counts updated 21h ago
OSOSCR
$OSCROscar Health, Inc.
$29.03+0.59%2.1k posts+14%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $OSCR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptCooling offAI verdict · as of 2026-07-17

Catching its breath after a run — could pick back up or fade from here.

ACA-insurer doubling year-over-year while its largest director exits with $70M+ into the strength.

Oscar Health is the technology-first health insurer that has repositioned itself as the go-to individual-marketplace (ACA/HIX) plan operator. The unit economics finally turned in early 2026 and the market has responded — but a large insider distribution is now the counter-signal.

What's driving the re-rate — and what has to be respected:

  • The Q1 print was a genuine inflection: revenue jumped 53% YoY to $4.65B with EPS of $2.28 vs a loss in Q4, driven by 2024-cohort seasonality plus HIX premium hikes flowing through the medical-loss ratio.
  • The multiple is still not stretched on forward numbers: trailing EPS is barely positive but consensus FY27 EPS is $1.04, putting forward P/E in the high 20s — reasonable for a business that's compounding revenue at 50%+ off a low base.
  • Director Mark Bertolini is a huge counter-tell: over $70M sold in six trading days at the end of June — the largest holder distributing into the recovery is exactly the kind of insider signal that historically caps a turnaround stock's near-term upside.
  • The 2027 HIX premium environment stays constructive: another +14% premium jump follows last year's +20%, giving Oscar a favorable pricing backdrop for members who stay on the exchange despite the political noise around ACA subsidies.

The forward look: the August 6 Q2 print is the referee. A clean beat plus a raised full-year MLR guide (community is expecting the raise) keeps the re-rating going; a soft Q2 or another Bertolini sale in the following week and the insider signal starts to look like tomorrow's news. The bigger overhang: the fate of the ACA enhanced subsidies in 2026 politics — a subsidy pullback would compress the entire book on renewal.

Agrees with X sentimentThe X 'raise bingo' setup and clean-flag chart-read match the operating momentum, and the +14% 2027 HIX premium math is real. Where we push back: none of the bullish threads engage with $70M+ of Bertolini distribution — the crowd is trading momentum, that's the risk signal it's ignoring.

What to watch: August 6 Q2 earnings and any raised full-year MLR guide; further Bertolini selling in the same week or an ACA subsidy pullback headline would turn the cooling into a reset.

On the calendar: 2026-08-06 — Q2 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment32 posts analyzed · as of 2026-07-15

Oscar Health chatter is bullish into Q2 earnings. Community expects a guidance raise (a 'raise bingo' has posters calling July 20 for the print). Bulls model 2026 MLR at 80% based on 2024 seasonality (~2.5% below management's low-end guide) and 2026 revenue at $19B (high end of guidance). HIX premiums are jumping +14% in 2027 following last year's +20%. Traders describe a clean flag setup and 'the trend is obvious.' Community lists OSCR as a 'must buy' at $32 alongside TEM/CLOV/BFLY on a $1M-by-EOY-2026 aspirational list. Long-term targets include $90-110. A minor rotation-out camp is trimming into NBIS or ZETA, but net sentiment is decisively long.

Read the AI verdict + X sentiment for $OSCR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Tech-enabled individual, small group, and Medicare Advantage health insurance with a member-facing digital platform.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Plans sits in its cycle right now — and what that implies for $OSCR.

Medical - Healthcare Plans · Healthcare

No material change from last week — Oscar Health's AI-driven clinical platform is gaining member growth while the UNH Medicaid fraud litigation adds regulatory risk to legacy insurers.

What this means for $OSCR

Partial — Tech-enabled individual, small group, and Medicare Advantage health insurance with a member-facing digital platform; the AI-driven clinical platform growth vs. government payer headwind is a secondary rather than primary near-term earnings catalyst.

Top industry ETF

$IHFiShares U.S. Healthcare Providers ETF
+17.4%YTD
+26.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-185.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
0.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
44.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-3.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
17.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 6, 2026$2.07$1.21+71.1%
Q4 2025Feb 10, 2026$-1.24$-0.92-34.6%
Q3 2025Nov 6, 2025$-0.53$-0.55+3.6%
Q2 2025Aug 6, 2025$-0.89$-0.90+1.1%
Next earningsThu, Aug 6·consensus EPS $0.41

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$4.6B+52.6%30.5%15.2%$2.28$2.6B
Q4 FY25$2.8B+17.3%6.6%-11.9%$-1.24$662.8M
Q3 FY25$3.0B+23.2%13.4%-4.3%$-0.53$-973.7M
Q2 FY25$2.9B+29.0%10.9%-8.0%$-0.89$499.8M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$18.5B$18.3B – $18.7B$1.04-$0.80 – $2.537
FY27$19.9B$19.6B – $20.2B$1.45$0.05 – $2.637
FY28$22.2B$22.1B – $22.3B$2.14$1.93 – $2.366
FY29$25.3B$23.2B – $26.2B$2.62$2.34 – $2.745
FY30$28.2B$25.9B – $29.2B$2.82$2.52 – $2.953

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.81%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+9.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+56.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 249.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.345-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 1Mario SchlosserDirector47.5K sh$1.5MSellJun 30Mark T BertoliniCEO624.2K sh$17.8MSellJun 29Mark T BertoliniCEO614.8K sh$18.0MSellJun 26Mark T BertoliniCEO591.2K sh$17.3MSellJun 25Mark T BertoliniCEO615.1K sh$17.6MSellJun 23Mario SchlosserDirector993.7K sh$29.2MSellJun 2Victoria BaltrusChief Accounting Officer1.5K sh$33KSellJun 2Mario SchlosserDirector34.1K sh$749KSellJun 2Janet LiangPresident12.5K sh$274KSellJun 2Blackley Richard ScottCFO31.7K sh$695K
1–10 of 19
+ 24 other (18 awards · 2 conversions · 2 exempts · 1 inkind · 1 gift) in window

See when $OSCR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 98-K — Item 5.07: Shareholder vote
AI summary

Oscar Health (OSCR) held its 2026 Annual Meeting on June 4, 2026, with all eight director nominees elected by wide margins and both advisory proposals (executive compensation and auditor ratification) approved. Nominees included Mark Bertolini, Joshua Kushner, Mario Schlosser, and five others; PricewaterhouseCoopers was ratified as auditor with 819.5M votes for vs. 710K against. The dual-class structure (Class A = 1 vote, Class B = 20 votes; 265.5M Class A and 35.6M Class B shares outstanding) means insider control remains dominant. This is a routine governance event with no immediate financial impact.

8-KPress release / Reg FDJun 88-K — Item 7.01: Press release / Reg FD
AI summary

Oscar Health (OSCR) disclosed on June 8, 2026 (Item 7.01, Reg FD) that it participated in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference at approximately 11:20 AM ET. The company provided a business update and reaffirmed its full year 2026 guidance as previously issued in the February 10, 2026 earnings press release. A webcast replay was made available at ir.hioscar.com. This is a routine investor relations disclosure; the guidance reaffirmation is the key signal, suggesting no material changes to OSCR's financial outlook.

8-KOfficer or director changeJun 28-K — Item 5.02: Officer or director change
AI summary

OSCR (OSCR) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in CEO. Individuals named in the filing include Oscar Health, Exact Name. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

8-KPress release / Reg FDApr 218-K — Item 7.01: Press release / Reg FD
AI summary

OSCR filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-21. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

8-KPress release / Reg FDMar 28-K — Item 7.01: Press release / Reg FD
8-KMaterial agreementFeb 108-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 2.03: Material debt obligation
+ 9 other (2 proxys · 2 13Gs · 1 10-Q · 1 earnings 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Why Fast-paced Mover Oscar Health (OSCR) Is a Great Choice for Value Investorszacks.com·1d agoOscar Health, Inc. (OSCR) Stock Sinks As Market Gains: What You Should Knowzacks.com·2d ago5 Multiline Insurers to Buy Amid Inflation, Softening Pricingzacks.com·2d agoOscar Health, Inc. (OSCR) Outpaces Stock Market Gains: What You Should Knowzacks.com·8d agoOscar Health, Inc. (OSCR) Stock Sinks As Market Gains: What You Should Knowzacks.com·11d ago

More in Medical - Healthcare Plans

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$UNH$CVS$ELV$CI$CNC$CLOV
Voices on X · top 9 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport